Last Update June. 21, 20133
Meiji Group
Ethical Pharmaceutical Business
Agricultural Chemicals and Veterinary Drugs Business
Unit for Confectionary Business
Unit for Dairy Products Business
Unit for Healthcare and Nutrition Business
Unit for International Business
Consolidated Sales$11.2B (Apr. 2012 – Mar. 2013)Consolidated Number of Employees15,338 (as of March 31st, 2012)
Last Update June. 21, 20134
Meiji Group Financial Overview
Consolidated Sales$11.2B
Operating Incomes$258M
*Based on the sales before intergroup elimination**Apr. 2012 - Mar. 2013
Confectionary and Healthcare
$4.07B30%
Pharmaceuticals$1.27B
10%
Others$1.84B
14%
Dairy Products$170M66%
Confectionary and Healthcare
$21M8%
Pharmaceuticals$64M25%
Others$2M1%
Dairy Products$6.17B
46%
1USD=100JPY
Last Update June. 21, 20136
2020 Vision
• Business Expansion through Proactive R&D
Investment
• Further Expansion of the Generic Drugs Business
• Proactive Expansion of International Business,
mainly in Asia and Emerging Countries
Contributing to the well-being of people worldwide through the research and development of ethical pharmaceuticals, agricultural chemicals and veterinary drugs, and by providing high-quality, low-priced generic drugs.
Last Update June. 21, 20137
R&D Administration
Non-consolidated Employees: 2,071 ( as of March, 2012)
R&D Expenditure: $150M (FY2012)
Intellectual PropertyPharmaceutical Research Center
M. MatsuoPresident & Representative Director
Agricultural & Veterinary Div.
Reliability & QA Center
K. Mori General Manager
International Headquarters
Production Div.
R&D Div.
Marketing Div.H. Uchida Senior Managing Executive Officer
Organization of Meiji Seika Pharma
Generics Development
Corporate Development
CMC Labs. Bioscience Labs.
S. Kurokawa Executive Officer
HR & General Affairs
Financial & Accounting
Audit
Drug Information Center
K. Noda General Manager
R. AsadaSenior Executive Officer Y. Murai Senior Executive Officer
Portfolio Management
New Product Planning and Creation
Partnering Strategy and Business Development
H. Yamaguchi Executive Officer
M. Egawa Executive Officer
Y. Sasaki Executive Officer
Last Update June. 21, 20138
Task : Drug Discovery & Research Operation, External Research Collaboration
New Product Planning and Creation Partnering Strategy and Business Development
Task : Agro-Vet Licensing, Generic Product Licensing,R&D Contract
Task : R&D Strategy, Portfolio Analysis & Optimization, Business Assessment and Valuation
New Product Planning and CreationGeneral Manager
Licensing and Product AcquisitionGroup Manager
Research Planning and Operation Group Manager
Licensing and Alliance ManagementGroup Manager
Business Development and Alliance ManagementGroup Manager
Executive Officer: Mr. Yuji Sasaki
Task : Strategic Alliance (incl. M&A),Business Development, Product & Technology Out-Licensing
Partnering Strategy and Business DevelopmentGeneral Manager
Portfolio Management General Manager
Task : Product In-Licensing, Marketing Alliance
Last Update June. 21, 20139
Employees (As of March, 2013)12 Branches and 76 Sales Offices
MR ca. 780(CNS specialized MR ca. 170 )R&D ca. 360
Headquarters (Kyobashi Tokyo)- Domestic Marketing Div.- Production Div.- International Div.- Reliability & QA Center- R&D Div.
Pharmaceutical Research Center &CMC Labs. (Yokohama)
Bioscience Labs. (Ashigara)
Business Locations & Group companies: Japan
Odawara Plant (Drug Formulation)
Kitakami Plant (API)Gifu Plant (API)
Group companies
・Ohkura Pharmaceutical
Manufacturing & sales of ethical pharmaceuticals
・Kitasato Pharmaceutical Industry
Sales of ethical vaccines
Ohkura Pharmaceutical (Kyoto)
Kitasato Pharmaceutical Industry (Tokyo)
Last Update June. 21, 201310 Beijing Office
Overseas Employees : 1,963
Business Locations: World
Shantou Meiji Pharmaceuticals Co., Ltd. (1989)
Production & Distribution
P.T. Meiji IndonesianPharmaceutical Industries (1974)Production, Distribution & Export
Thai Meiji Pharmaceuticals Co., Ltd. (1979)Production, Distribution & ExportTedec-Meiji
Farma, S.A. (1991)Production, Distribution & Export
Los Angeles Office
Meiji Pharma (Shandong) Co., Ltd. (2004)
Fermentation Production
Dong-A Meiji Bio Limited. (2012)Monoclonal Antibody Production
Meiji Pharma Korea Co., Ltd. (2012)Distribution (Agrochemicals)
Last Update June. 21, 201311
Consolidated basis$1,273M
Ethical Pharmaceuticals$1,056M
- domestic sales- overseas sales- export
AgrochemicalsAnimal Health$217M
Segment Sales
Apr. 2012 - Mar. 2013
83%
17%
1USD=100JPY
Last Update June. 21, 201312
Ethical Pharmaceutical Sales by Therapeutic Area in the Japanese market ( Apr.2012―Mar.2013 )
Meiact®Fosmicin®
Isodine®
Habekacin®
Omegacin®
Orapenem ®
Sword®
Meilax® ( Ethyl Loflazepate ) : AnxietyDepromel® ( Fluvoxaime ) : Depression, OCD, SADReflex® ( Mirtazapine ) : DepressionDiacomit ®( Stiripentol ) : Antiepileptic
Ebastel® ( Ebastin ): Urticaria, RhinitisDaunomycin: Acute LeukemiaTherarubicin® ( Pirarubicin ) : Malignant LymphomaLaserphyrin (Talaporfin Sodium ): Lung CarcinomaOxis® 9µg Turbuhaler® ( Formoterol ) : COPD
Infection (33%)$280M
CNS (26%)$219M
Others (10%)$82M
Generics (31%)$265M
Total$846M
Last Update June. 21, 201313
Brand Name Activity/Indication Sales in Japan Partner(Date of Launch)
Meiact (’94.6) Oral cephem $167M Reflex (’09.9) NaSSA* : Depression $136M MSD
Depromel (’99.5) SSRI: Depression, OCD, SAD $48M Abbott
Vancomycin MEEK (’02.7) Antibiotic $38M Kobayashi Kako
Amlodipine (’08.7) Ca antagonist $38MFosmicin (’80.12) Fosfomycin $36MMeilax (’88.12) Benzodiazepine: Anxiety $34M Sanofi-Aventis
Sulbacillin (’06.9) Antibiotic $22MOrapenem (’09.8) Oral carbapenem $21M Pfizer
Isodine (’61.11) Anti-septic $21M Mundipharma
Donepezil (’11.11) Anti-Alzheimer’s disease $19MEbastel (’96.6) H1antagonist: Urticaria, Rhinitis $18M Dainippon Sumitomo
Omegacin (’02.3) Carbapenem $14M Pfizer
Habekacin (’90.12) Aminoglycoside: MRSA $13M
Ethical Pharmaceutical Leading Products in the Japanese Market ( Apr.2012―Mar.2013 )
* NaSSA : Noradrenergic and Specific Serotonergic Antidepressant
【Infectious Disease】
Compound Activity Indication Status Partner
ME1111 Antifungal Onychomycosis Phase I
Sym006 Polyclonal human antibodies
Pseudomonas aeruginosa infection
Preclinical
Research Collaboration with Symphogen
Last Update June. 21, 201314
Product Pipeline : Infection Disease
Developing outside Japan Meiji Seika Pharma original compound
【CNS】
Compound Activity Indication Status Partner
ME2136(Asenapine)
SDA Schizophrenia Phase IIIMSD(in-license)
Depromel(Fluvoxaime)
SSRI Obsessive Compulsive Disorder ( Pediatric )
Phase IIILine Extension
Abbvie(in-license)
ME2112(Ziprasidone) SDA Schizophrenia Phase II
RaQualia(in-license)
Reflex(Mirtazapine)
NaSSA FibromyalgiaPhase IILine Extension
MSD(in-license)
ME2125(Safinamide)
MAO-B inhibitor Parkinson’s Disease Phase INewron(In-license)
Last Update June. 21, 201315
New Product Pipeline : CNS
Developing in Japan
Last Update June. 21, 201316
New Product Pipeline : Unmet Medical Needs
【Unmet Medical Needs】
Compound Activity Indication Status Partner
ME2906 PhotosensitizerGlioma
Esophagus Cancer
NDAClinical Research
ME3113(Udenafil)
Phosphodiesterase V inhibitor
Benign Prostatic Hyperplasia Phase IIb
Dong-A(In-license)
DMB-3111(Biosimilar)
Monoclonal Antibody Breast Cancer Preclinical Dong-A
Developing in JapanDeveloping outside Japan
Last Update June. 21, 201317
Partners’ Development Activities
【International Development】
Compound Activity Indication Status Partner
LS11(ME2906) Photosensitizer
Hepatocellular CarcinomaMetastatic Colorectal CancerBenign Prostatic Hyperplasia
Phase IIIPhase IIIPhase I
Light Sciences Oncology(out-license)
ME3301 Anti-inflammatory IBD, Allergic Rhinitis Phase II Amalyte(out-license)
CP8816 & CP8863
Progesterone receptor modulator Endometriosis Preclinical
Tokai(out-license)
MN-447 (CP4715)
GPⅡbⅢa & αvβ3 receptor dual antagonist
Acute Ischemic Heart Disease Cerebral Infarction
PreclinicalMediciNova(out-license)
Developing in JapanDeveloping outside Japan
Meiji Seika Pharma original compound
Recent Alliance Deals
Last Update June. 21, 201318
Year Partner Type of CollaborationApr/2013 MSD In license of Asenapine / Schizophrenia in Japan
Oct/2012 OHKURA Distribution of Check hMPV / Diagnostic reagent kit in Japan
May/2012 AstraZeneca Distribution of Oxis® 9µg Turbuhaler®28doses / COPD in Japan
May/2012 OHKURA Distribution of Check AD / Diagnostic reagent kit in Japan
Apr/2012 R-Pharm Out license and Distribution of MEIACT MS® and ADANT® in Russia
Apr/2012 Thien Thao Distribution partnership of Meiji products in Viet Nam
Jan/2012 Newron In license of Safinamide / Parkinson’s Disease In Asia
Dec/2011 OHKURA Distribution of Check RSV/ Diagnostic reagent kit in Japan
Sep/2011 Dong-A Pharm Strategic Partnership for global R&D of Biosimilars
Sep/2011 Dong-A Pharm In license of Udenafil / Benign Prostatic Hyperplasia in Japan
Jul/2011 Alere Medical Distribution of Clearline®InfluenzaA/B/(H1N1)2009 / Diagnostic product for Influenza in Japan
Mar/2011 RaQualia In license of Ziprasidone / Schizophrenia in Japan
Jan/2011 Fresenius KabiJapan Strategic Partnership of oncologic generic products in Japan
Last Update June. 21, 201319
Strategic Alliance to Strengthen Generic Business
Global Alliance with Dong-A Pharmaceutical
(September 14th, 2011)
Collaboration on Monoclonal Antibody of Biosimilars
・ DMB-3111 selected for development for oncology indications
・Two more to be selected within a year
Joint Venture established for global supply and commercialization
c-GMP manufacturing facility to be constructed in Incheon Free Economic Zone
Last Update June. 21, 201320
Partnering Interest
• Product In-license & Research Collaboration• Infectious and respiratory diseases• CNS diseases• Diseases with unmet medical needs
(Oncology, Inflammatory & rare diseases)• Marketing Collaboration
• ENT• Pediatric• Psychiatry & Neurology• Respiratory• Hematology